Floatz logo

Tocilizumab

Stage III Urethral Cancer AJCC v8

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Stage III Urethral Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
Vinflunine
Dr Anders Ullén
Phase 2BB
Pembrolizumab
Emory University
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Jonsson Comprehensive Cancer Center
Phase 1/2B
Nivolumab
M.D. Anderson Cancer Center
Phase 2B

View all 30 →

Same molecule, other indications

Tocilizumab is also rated in:

rheumatoid arthritisDormant
BB
Indicative ·
66 / 100
View asset →
COVID-19Dormant
BB
Indicative ·
65 / 100
View asset →
acute chest syndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →